BioCentury | Jan 29, 2015
Product R&D

Company checkpoints

The spate of biotechs announcing new targets, combinations or milestones in the PD-1 space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of...
Items per page:
1 - 1 of 1